Key Takeaways
- Flat revenue masks underlying growth: Reported revenue was flat YoY, but an accounting change for a new UAE defense contract suppressed the top line by INR23 crores; adjusted growth would have been 7%.
- H2-weighted year ahead: 70% of BTS invoicing is concentrated in H2, so the margin recovery and cash generation story is back-loaded, with Q2 further slowed by the French summer.
- Subsidiary turnaround is the margin unlock: Restructuring has lifted the sub’s EBITDA margin from negative to 3%, and further improvement is the single biggest lever to hit the consolidated 10%-11% target.
- Order book normalizing, not shrinking: EMS orders have returned to a 6-9 month horizon from pandemic-era extended lead times, while BTS carries a 2+ year visibility; the pipeline is healthy in both North America and domestic defense.
- What to watch next quarter: Whether the French subsidiary’s seasonally weak Q2 still shows YoY margin progress, and whether North American customer qualifications convert to orders by year-end as guided.
The UAE Contract & Accounting Distortion
- A win that hid itself: A significant new UAE defense customer was added, with an order worth \$9-10 million to be delivered this year, but auditors required net-basis accounting until customer-supplied inventory is consumed, compressing reported revenue.
- Mechanical, not economic: The accounting treatment recognized only INR4 crores against INR23 crores of gross invoicing, a purely balance-sheet-driven drag that reverses once the contract converts to a regular turnkey model.
- Growth restated: Management expects 18%-20% growth on a gross accounting basis for FY25, with net accounting reducing the reported top line by 5%-6%; the underlying business trajectory is unchanged.
Nikhil Mallavarapu: "The auditors have asked us to account it on a net basis rather than a gross basis. For the quarter, as mentioned, the impact from the top line only was to the tune of about INR23 crores."
Margin Bridge & Recovery Path
- Standalone margin hit by mix: EBITDA margin declined because the high-margin BTS segment contributed only 26% of revenue; raw material cost appeared elevated as a percentage, but this is a mix effect, not input-cost inflation.
- Subsidiary restructuring paying off: EBITDA margin improved to 3% from negative 0.7% YoY, driven by manpower and cost actions taken over the past six months; these expense levels are expected to be maintained.
- The H2 skew is structural: 70% of BTS defense invoicing lands in H2, with a tilt toward Q4, a pattern management describes as typical for the industry; Q2 is additionally slowed by fewer invoicable working days during the French summer.
- Employee cost trajectory: Standalone employee costs run at ~15% of revenue with marginal operating leverage possible; the subsidiary’s costs rise proportionately with revenue, so the strategy is to shift more manpower to India to improve gross margin.
- Debt reduction feasible despite H2 skew: Customer advances on new orders plus the H2 BTS cash conversion are expected to bring net debt down to ~INR180 cr by September and ~INR170 cr by year-end, with interest cost holding at INR35-40 cr.
Nikhil Mallavarapu: "We expect the majority of it to happen in H2. As I mentioned, there are two factors. One is the BTS defense business where we are expecting almost 70% of our invoicing to happen in the second half of the year."
Segment Dynamics
| Segment | Trend | Commentary |
|---|---|---|
| BTS (Build-to-Spec) | ▼ Soft Q1, ▲ H2 recovery | Domestic defense and space orders skewed to H2; operates in high-end areas (radar, electronic warfare) where the Make in India pie is expanding. |
| EMS (Electronics Manufacturing) | ▲ Growth driver | Roughly half is defense/aerospace (missiles, radios, air traffic management); industrial includes grid and industrial automation; transport covers railways and EV components for heavy vehicles; healthcare includes digital radiography. Recurring in nature with quarterly fluctuation. |
| Engineering Services | ▬ Shifting model | Reducing exposure to high-risk fixed-price contracts, moving toward shorter-horizon service and consulting engagements. |
| Subsidiary (France) | ▲ Improving | Restructuring drove margin from negative to 3%; Q2 seasonally slower, Q3 and Q4 stronger; target growth is high single digit to ~10%. |
- Defense and aerospace is the FY25 growth engine: Management named it the biggest contributor, with strong BTS order intake expected from space defense satellites, radars, and land systems for tanks.
- Competitive positioning: The company leans on export-oriented EMS with a China Plus One advantage, plus BTS IP creation (e.g., passenger information systems for railways) where few competitors exist; existing players are becoming more aggressive as the opportunity pool grows.
K.S. Desikan: "The BTS business, the domestic defense space et cetra, I think the opportunity is exploding in terms of Make in India or the positive indigenization list. The pie is only increasing and we choose to operate at a certain high end of the technology areas like the radar, electronic warfare, et cetera."
Order Book & Pipeline
- EMS order horizon normalizing: Orders have returned to a 6-9 month visibility window after the extended lead times of the supply-chain disruption era; BTS orders carry a 2+ year horizon.
- North American pipeline in qualification: Healthy demand from North American customers currently in the qualification phase, with orders expected to be secured by year-end.
- Domestic pipeline broad-based: Opportunities span defense, space, and the railway segment, supported by the positive indigenization list.
- New customer contribution: Management estimated, without precision, that new customers could contribute 10%-15% of revenue, though it declined to split the 18%-20% growth target between repeat and new business.
Risks & Watchpoints
- Supply chain risk is specific, not systemic: The one flagged risk is delivery of PCB boards from the French supply base for one large customer; mitigating actions are underway and management considers the full-year numbers still achievable.
- Working capital normalization expected: Working capital days are expected to return to March levels of about 61 days by end of September, a key assumption behind the debt reduction path.
- Management declined to size the TAM: When asked for a geography-wise addressable market, management called it "a bit of a difficult question to answer," arguing the markets are "massive" and growth rates plus customer additions are the more relevant metrics.
Nikhil Mallavarapu: "One area of risk which we continue to monitor closely is around the delivery of their PCB boards from our supply base in France, which is specific to one of our large customers in the segment. Having said that, we are taking various mitigating actions to address that well in advance."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth (gross basis) | 18%-20% | FY25 |
| Net accounting drag on top line | 5%-6% reduction | FY25 |
| Standalone EBITDA margin | 13%+ | FY25 full-year |
| Consolidated EBITDA margin | 10%-11% (excluding other income) | FY25 full-year |
| Working capital days | Return to ~61 days | End of September |
| Net debt | Reduce to ~INR180 cr | End of September |
| Net debt | Reduce to ~INR170 cr | Year-end |
| Interest cost | INR35-40 cr | FY25 |
| Standalone growth rate | 25%+ | Medium-term target |
| Subsidiary growth rate | High single digit to ~10% | Medium-term target |
| Consolidated EBITDA margin | 13%-15% | Medium-term target |
| North American orders | Secured from customers in qualification | By year-end |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue from operations (consolidated) | ₹246 cr, flat YoY |
| Adjusted revenue (gross basis) | ₹264.5 cr, +7% YoY adjusted for net accounting of a contract |
| EBITDA (consolidated) | ₹16 cr, down YoY |
| EBITDA margin (consolidated) | 6.34%, down YoY |
| Standalone EBITDA margin target (full year) | ~13%+ |
| Consolidated EBITDA margin target (full year) | 10% to 12% |
| Consolidated revenue growth target (full year, gross basis) | ~18% |
| BTS revenue contribution | 26% of total revenue, vs 30% in FY24 |
| BTS full-year revenue contribution target | ~30% |
| Subsidiary EBITDA margin | 3%, improved from -0.7% in Q1 FY24 |
| Order book | ~₹1,600 cr, with 13-15 months average execution period |
| Order book mix (ER&D / EMS / BTS) | ~32% / ~42% / ~30% |
| Net debt (consolidated) | ₹190 cr, expected to reduce to ~₹180 cr by Sep and ~₹170 cr by year-end |
| Working capital increase over March levels | ₹20-25 cr |
| Top 5 customer revenue concentration | ~50% of overall revenue |